Agomab Therapeutics NV

AGMB · NASDAQ

$9.05−$0.21 (−2.27%)TodayMarket closed · Oct 23, 7:59 PM ET

Prev close $9.26

Latest news

Press releaseOct 13, 4:05 PM ETGlobe Newswire
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
Press releaseOct 8, 4:05 PM ETGlobe Newswire
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
NewsOct 1, 2:31 PM ETVandana Singh
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
NewsOct 1, 6:38 AM ET
Agomab Therapeutics Announces Results From 48-Week OLE Portion Of Its Phase 2A STENOVA Trial Evaluating Ontunisertib In Patients With Severe Crohn's Disease; Favorable Safety And Tolerability Profile Maintained Through Up To 60 Weeks Of Treatment; Low Annualized FSCD-Related Event Rate Of 3%
Press releaseOct 1, 6:30 AM ETGlobe Newswire
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
Press releaseSep 14, 4:05 PM ETGlobe Newswire
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
Press releaseSep 11, 4:05 PM ETGlobe Newswire
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Press releaseAug 6, 4:01 PM ETGlobe Newswire
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
NewsJun 23, 4:13 PM ET
Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib
Press releaseJun 23, 4:05 PM ETGlobe Newswire
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
Press releaseApr 23, 6:14 PM ETGlobe Newswire
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
NewsFeb 11, 8:02 AM ETAvi Kapoor
Mattel Posts Downbeat Earnings, Joins Lyft, Robinhood And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
NewsFeb 10, 8:03 AM ETAvi Kapoor
Goodyear Tire Posts Downbeat Earnings, Joins BP, ON Semiconductor And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease

Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation

Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial

Agomab Therapeutics Announces Results From 48-Week OLE Portion Of Its Phase 2A STENOVA Trial Evaluating Ontunisertib In Patients With Severe Crohn's Disease; Favorable Safety And Tolerability Profile Maintained Through Up To 60 Weeks Of Treatment; Low Annualized FSCD-Related Event Rate Of 3%

Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease

Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Mattel Posts Downbeat Earnings, Joins Lyft, Robinhood And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Goodyear Tire Posts Downbeat Earnings, Joins BP, ON Semiconductor And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session